These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21498984)

  • 1. [Efficacy of vinorelbine in advanced and metastatic breast cancer].
    Nishikawa N; Ohmura T; Suzuki Y; Kameshima H; Kutomi G; Hirata K
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):577-80. PubMed ID: 21498984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of vinorelbine monotherapy in advanced and metastatic breast cancer].
    Suehisa H; Aogi K; Hara F; Takabatake D; Takashima S; Ohsumi S; Takashima S; Komatsubara K
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1709-12. PubMed ID: 18931573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effect of Vinorelbine monotherapy in 18 cases of advanced or metastatic breast cancer].
    Sasada S; Ohtani S; Kim R; Higaki K
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1703-7. PubMed ID: 18931572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer.
    Wang Y; Liu J; Jia W; Li S; Rao N; Su F; Liu Q; Yao H
    Chemotherapy; 2017; 62(1):71-79. PubMed ID: 27648841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
    Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
    Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
    Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
    Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
    Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
    Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
    J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.
    Mansour M; Mourad C
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):429-35. PubMed ID: 23801283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
    Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
    BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effects of vinorelbine-based chemotherapy--retrospective study of 65 patients with metastatic or relapsed breast cancer].
    Watanabe K; Otake T; Yasuda M; Takenoshita S
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):51-6. PubMed ID: 20087032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
    Ahn JH; Kim SB; Kim TW; Ahn SH; Kim SM; Park JM; Lee JS; Kang YK; Kim WK
    J Korean Med Sci; 2004 Aug; 19(4):547-53. PubMed ID: 15308846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.
    Rossi A; Gridelli C; Gebbia V; Rosati G; Tortoriello A; Maione P; Borsellino N; Rossi N; Pisano A; Colantuoni G; Iaffaioli RV; Castaldo V; Manzione L
    Anticancer Res; 2003; 23(2C):1657-64. PubMed ID: 12820437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.